Lung
Study Name: Destiny Lung 04
- Cancer Stage: III or IV
- Key Inclusion: Non-Squamous NSCLC; HER2+ in exons 19 or 20
- Description: A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
- Study Number: D967SC00001
- NCT#: NCT05048797
Study Name: Henlius
- Cancer Stage: I-III
- Key Inclusion: LS-SCLC; treatment naïve
- Description: A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
- Study Number: HLX10-020-SCLC302
- NCT#: NCT05353257
Study Name: CYBRID-01
- Cancer Stage: I-III
- Key Inclusion: CT guided Bx
- Description: Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-01)for Participants with Stage IV Lung Cancer.
- Study Number: ELEP-2022-CYBRID-01
- NCT#: NCT05478538
Study Name: Tempus Gemini
- Cancer Stage: All
- Key Inclusion: Cohort 1: Known/suspected NSCLC w/curative intent; Cohort 2: Stage IV
- Description: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC).
- Study Number: Tempus Gemini
- NCT#: NCT05236114
Study Name: SOHO 02
- Cancer Stage: III or IV
- Key Inclusion: NSCLC with HER2 mutations
- Description: A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)
- Study Number: SOHO-02
- NCT#: NCT06452277
Study Name: PACIFIC-8
- Cancer Stage: III
- Key Inclusion: Unresectable; concurrent chemo radiation
- Description: A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable Non-small cell Lung Cancer
- Study Number: D9075C00001
- NCT#: NCT05211895
Study Name: Teligene
- Cancer Stage: III or IV
- Key Inclusion: NSCLC; EGFR +
- Description: A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non Small Cell Lung Cancer
- Study Number: TL-EGFR-2201
- NCT#: NCT06010329
Study Name: TROPION-Lung10
- Cancer Stage: III or IV
- Key Inclusion: Non-Squamous NSCLC with PD-L1+; no actionable mutations
- Description: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous Non Small Cell Lung Cancer With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Study Number: D7632C00001
- NCT#: NCT06357533
Study Name: Teligene
- Cancer Stage: III or IV
- Key Inclusion: NSCLC; non-resistantUncommon EGFR +
- Description: Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Study Number: SZCT-2020-06
- NCT#: NCT05168566
Study Name: Triton
- Cancer Stage: IV
- Key Inclusion: Non-Squamous NSCLC; STK11, KEAP1, or KRAS mutations; no ALK
- Description: A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients
- Study Number: D419ML00003
- NCT#: NCT06008093
Study Name: GEMINI-NSCLC
- Cancer Stage: I-III
- Key Inclusion: NSCLC
- Description: NSCLC Biomarker Study
- Study Number: TP-CA-002
- NCT#: NCT05236114
Study Name: FUJIFILM(FF10832-PEM-201)
- Cancer Stage: N/A
- Key Inclusion: Progressive disease during/within 12 weeks of treatment with PD-(L)1 inhibitor
- Description: A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
- Study Number: FF-10832
- NCT#: NCT05318573
Study Name: Tale EAP
- Cancer Stage: IV
- Key Inclusion: NSCLC; ROS1+
- Description: Expanded Access Program of Taletrectinib in Patients with Advanced or Metastatic ROS1-Positive NSCLC
- Study Number: AB-106-EAP
- NCT#: NCT06841874
Study Name: RASolve 301
- Cancer Stage: IV
- Key Inclusion: NSCLC, KRAS, NRAS, HRAS
- Description: Study of Daraxonrasib (RMC-6236) in Previously Treated Patients With RAS Mutated NSCLC
- Study Number: RMC-6236-301
- NCT#: NCT06881784
-
Frederick, MD 21702
301-694-5861 More Information -
Frederick, MD 21702
301-663-4774 More Information -
Frederick, MD 21702
240-215-6310 More Information -
Frederick, MD 21702
301-694-5580 More Information -
Frederick, MD 21702
240-566-4100 More Information -
Frederick, MD 21702
240-566-4100 More Information -
Frederick, MD 21702
240-566-4500 More Information
/
View All